Clinical Trials
We Forge a More Promising Path Forward for Your Will to Fight
We are driven by a single purpose:
to turn groundbreaking science into new hope for patients battling difficult-to-treat cancers and neurodegenerative diseases. Clinical trials are a critical step in this journey, offering access to innovative investigational therapies before they are widely available.
We invite doctors and patients to explore the clinical studies listed below. Each trial represents a potential new path forward and a step closer to a cure.
Clinical trials recruiting now
We are currently recruiting patients for 4 clinical trials in a range of indications.
If you or someone you care about is battling cancer, we welcome you to learn more and get in touch.
BIPAVE-001
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Indications: advanced or metastatic non-small cell lung cancers, colorectal cancers and angiosarcoma.
PRESERVE-003
A Phase 3 study of gotistobart versus docetaxel
Indications: Squamous cell carcinoma of the lung that progressed on chemotherapy and PD-1/PD-L1 inhibitor immunotherapy.
PRESERVE-006
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan
Indications: Metastatic Castration-resistant Prostate Cancer
ONC-841-002
Safety, Pharmacokinetics (PK) and Efficacy of ONC-841 in Advanced Solid Tumors NCT06352359
Indications: Advanced or metastatic cancers
Active clinical trials not recruiting
Our heartfelt gratitude goes out to every patient, caregiver, and family who participated in these important trials. Our commitment continues, and we look forward to sharing the important learnings with the medical community in the future.
PRESERVE-001
A Phase 1 open-label study of gotistobart as a monotherapy and in combination with Pembrolizumab
Indications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
PRESERVE-004
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab
Indications: Platinum-resistant ovarian cancer
PRESERVE-006
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan
Indications: Metastatic Castration-resistant Prostate Cancer
PRESERVE-004
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab
Indications: Platinum-resistant ovarian cancer
Clinical trials recruiting soon
For further inquiries about our clinical trials, don’t hesitate to reach out.